Details of Disease

General Information of Disease (ID: DISGDM2Z)

• Disease Name: Meningococcal disease
• Disease Class: 1C1C: Meningococcal disease
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISGDM2Z: Meningococcal disease
• ICD Code: ICD-11: ICD-11: 1C1C
• Disease Identifiers:
  MONDO ID: MONDO_0005373
  MESH ID: D008589
  UMLS CUI: C0025303
  MedGen ID: 7537
  SNOMED CT ID: 23511006

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Menveo	DMA7PDJ	Approved	Vaccine	[1]

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
GSK4023393A	DMC6K19	Phase 2	Vaccine	[2]
SP0230	DM4U99D	Phase 1/2	Vaccine	[3]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 12 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CFH	TTUW6OP	Limited	Genetic Variation	[4]
DHPS	TTBO2A9	Limited	Biomarker	[5]
ENAH	TTY36UA	Limited	Biomarker	[6]
ALCAM	TT2AFT6	Strong	Genetic Variation	[7]
CD46	TTMS7DF	Strong	Biomarker	[8]
CES1	TTMF541	Strong	Genetic Variation	[7]
CFD	TT8D13I	Strong	Biomarker	[9]
CPB2	TTP18AY	Strong	Altered Expression	[10]
GRM5	TTHS256	Strong	Genetic Variation	[7]
TMPRSS15	TTXL0GC	Strong	Genetic Variation	[7]
CFP	TTLA0VS	Definitive	Genetic Variation	[11]
FCGR2B	TT5RWKQ	Definitive	Genetic Variation	[12]

This Disease Is Related to 21 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ACE	OTDF1964	Limited	Altered Expression	[13]
ADD1	OTTF68DC	Limited	Genetic Variation	[14]
ALKBH1	OTADGU5D	Limited	Biomarker	[15]
BPIFA1	OTQFD2J5	Limited	Genetic Variation	[16]
CFHR1	OT72R16T	Limited	Genetic Variation	[17]
DEFA4	OTOQWE4C	Limited	Biomarker	[18]
NMB	OT4NLN6H	Limited	Biomarker	[19]
CFHR3	OTYL8SDO	moderate	Genetic Variation	[17]
ADAM32	OTUJR3Q3	Strong	Genetic Variation	[7]
AP2M1	OTQCOSFN	Strong	Biomarker	[20]
C5AR2	OTP1Q82J	Strong	Biomarker	[21]
C7	OTZ27VJN	Strong	Biomarker	[22]
CNTNAP5	OTF0AAJD	Strong	Genetic Variation	[7]
FBXO15	OTJHEFE5	Strong	Genetic Variation	[7]
IL4I1	OTK54C63	Strong	Genetic Variation	[7]
MYO16	OTMS3D8W	Strong	Genetic Variation	[7]
NUP62	OTMN63DH	Strong	Genetic Variation	[7]
OLA1	OTAPOTTG	Strong	Genetic Variation	[7]
PRDM11	OT6DX554	Strong	Genetic Variation	[7]
FCGR2C	OTNLMNYB	Definitive	Genetic Variation	[12]
SFTPA2	OT6SFOMU	Definitive	Genetic Variation	[23]

References

• [1] FDA Approved Drug Products from FDA Official Website.
• [2] Clinical pipeline report, company report or official report of GlaxoSmithKline
• [3] Clinical pipeline report, company report or official report of Sanofi
• [4] The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?.Pediatr Nephrol. 2019 Aug;34(8):1349-1367. doi: 10.1007/s00467-018-4042-z. Epub 2018 Aug 23.
• [5] PCR amplicon restriction endonuclease analysis of the chromosomal dhps gene of Neisseria meningitidis: a method for studying spread of the disease-causing strain in contacts of patients with meningococcal disease.J Clin Microbiol. 1995 May;33(5):1174-9. doi: 10.1128/jcm.33.5.1174-1179.1995.
• [6] Meningococcal vaccination in pregnancy.Hum Vaccin Immunother. 2018 May 4;14(5):1188-1196. doi: 10.1080/21645515.2018.1445447. Epub 2018 Mar 21.
• [7] Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease.Nat Genet. 2010 Sep;42(9):772-6. doi: 10.1038/ng.640. Epub 2010 Aug 8.
• [8] CD46 accelerates macrophage-mediated host susceptibility to meningococcal sepsis in a murine model.Eur J Immunol. 2017 Jan;47(1):119-130. doi: 10.1002/eji.201646397. Epub 2016 Dec 21.
• [9] Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections.Blood. 2006 Jun 15;107(12):4865-70. doi: 10.1182/blood-2005-07-2820. Epub 2006 Mar 9.
• [10] Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children.J Thromb Haemost. 2008 Feb;6(2):268-76. doi: 10.1111/j.1538-7836.2008.02841.x. Epub 2007 Nov 15.
• [11] Properdin deficiency in a large Swiss family: identification of a stop codon in the properdin gene, and association of meningococcal disease with lack of the IgG2 allotype marker G2m(n).Clin Exp Immunol. 1999 Nov;118(2):278-84. doi: 10.1046/j.1365-2249.1999.01056.x.
• [12] Meningococcal disease and polymorphism of FcgammaRIIa (CD32) in late complement component-deficient individuals.Clin Exp Immunol. 1998 Jan;111(1):97-101. doi: 10.1046/j.1365-2249.1998.00484.x.
• [13] Angiotensin-converting enzyme genotype may predict survival following major trauma.Emerg Med J. 2008 Nov;25(11):759-61. doi: 10.1136/emj.2006.045336.
• [14] Single nucleotide polymorphisms in genes of circulatory homeostasis in surviving pediatric intensive care patients with meningococcal infection.Pediatr Crit Care Med. 2008 Sep;9(5):517-23. doi: 10.1097/PCC.0b013e318184985b.
• [15] ABH secretor status, as judged by the Lewis phenotypes, in Norwegian survivors from meningococcal disease.APMIS. 1993 Oct;101(10):791-4. doi: 10.1111/j.1699-0463.1993.tb00181.x.
• [16] A Rare Mutation in SPLUNC1 Affects Bacterial Adherence and Invasion in Meningococcal Disease.Clin Infect Dis. 2020 May 6;70(10):2045-2053. doi: 10.1093/cid/ciz600.
• [17] Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome.Mol Immunol. 2015 Oct;67(2 Pt B):276-86. doi: 10.1016/j.molimm.2015.06.021. Epub 2015 Jul 7.
• [18] Polymorphisms in PARP, IL1B, IL4, IL10, C1INH, DEFB1, and DEFA4 in meningococcal disease in three populations.Shock. 2010 Jul;34(1):17-22. doi: 10.1097/SHK.0b013e3181ce2c7d.
• [19] Lipooligosaccharide structure contributes to multiple steps in the virulence of Neisseria meningitidis.Infect Immun. 2006 Feb;74(2):1360-7. doi: 10.1128/IAI.74.2.1360-1367.2006.
• [20] Hereditary properdin deficiency in three families of Tunisian Jews.Acta Paediatr. 1993 Sep;82(9):744-7. doi: 10.1111/j.1651-2227.1993.tb12550.x.
• [21] Distinct roles of the anaphylatoxin receptors C3aR, C5aR1 and C5aR2 in experimental meningococcal infections.Virulence. 2019 Dec;10(1):677-694. doi: 10.1080/21505594.2019.1640035.
• [22] Two mutations of the C7 gene, c.1424G > A and c.281-1G > T, in two Korean families.J Clin Immunol. 2006 Mar;26(2):186-91. doi: 10.1007/s10875-006-9006-6. Epub 2006 Mar 22.
• [23] Genetic susceptibility to meningococcal infection.Expert Rev Anti Infect Ther. 2013 Feb;11(2):187-99. doi: 10.1586/eri.12.161.